Oral heparin Emisphere

IDrugs

Volumn 3, Issue 7, 2000, Pages 817-824

  Dunn, Andrew ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33748370750     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Elan Corporation plc & Emisphere Technolgoies Inc in $15 million joint venture and drug delivery alliance. Elan Corp Plc PRESS RELEASE 1995 October 19
2. Elan/Emisphere Technologies joint venture for oral heparin/heparinoids. FDC REPORTS PINK SHEET 1995 57 46 T&G-11 - T&G-12
3. N-acylated α-amino acids as novel oral delivery agents for proteins. Leone-Bay A, Santiago N, Achan D, Chaudhary K, DeMorin F, Falzarano L, Haas S, Kalbag S, Kaplan D, Leipold H, Lercara C et al J MED CHEM 1995 38 4263-4269
4. Emisphere gears up for heparin IND. SCRIP 1996 2107 10
5. Emisphere files IND for oral heparin. SCRIP 1996 2116 18
6. Product news in brief. SCRIP 1996 2164 26
7. Emisphere and Elan finalize joint venture agreement Emisphere Technologies Inc PRESS RELEASE 1996 September 27
8. Elan/Cytogen form oncology venture. SCRIP 1996 2169 7
9. Emisphere's progress with oral heparin. SCRIP 1996 2181 22
10. Emisphere announces presentation of oral heparin clinical data at American Heart Association Meeting. Emisphere Technologies Inc PRESS RELEASE 1996 November 13
11. Elan Corp Plc ANNUAL REPORT 1996 9-15
12. Emisphere receives notice of allowance for composition of matter patent on oral heparin carrier. Emisphere Technologies Inc PRESS RELEASE 1997 March 04
13. Emisphere receives notices of allowance for mechanism of action and oral vaccine patents. Emisphere Technologies Inc PRESS RELEASE 1997 April 25
14. Highlights of the 213th Meeting of the American Chemical Society (Part V), San Francisco, USA. Waterhouse R IDDB MEETING REPORT 1997 April 13-17
15. Emisphere reports third quarter 1997 results. Emisphere Technologies Inc PRESS RELEASE 1997 June 16
16. Emisphere announces therapeutic heparin levels achieved with formulated oral heparin preparation in clinical trial. Emisphere Technologies Inc PRESS RELEASE 1997 July 14
17. Emisphere commences offering of one million shares of common stock. Emisphere Technologies Inc PRESS RELEASE 1997 July 21
18. Disposition in cynomolgus monkeys of the oral delivery agent P414 following iv and po dosing. Baughman RA, Rivera T, Chamberland G, Kinzig M, Sorgel F PHARM RES 1996 13 9 Suppl S508
19. Pharmacological profile of oral heparin using derivatized non-α-amino acids. Rivera T, Baughman RA, Leipold H, Rosado C, Kutzy T, Mayer E, Leone-Bay A PHARM RES 1996 13 9 Suppl S326
20. Preformulation studies with CADDSYS carrier P414. Agarwal R, Chaudhary K, Barantsevich E, Harris E, Ho K-K, Baughman RA PHARM RES 1996 13 9 Suppl S280
21. Measurement of P414 in monkey plasma samples by LC-MS-MS. Leone-Bay A, Kinzig M, Ruesing G, Mueller C, Baughman Jr RA, Soergel F PHARM RES 1996 13 9 Suppl S51
22. Emisphere presents oral heparin clinical data and oral low molecular weight heparin data at AAPS meeting. Emisphere Technologies Inc PRESS RELEASE 1997 November 07
23. Emisphere and Elan announce successful completion of additional clinical trials for oral heparin preparation. Emisphere Technologies Inc PRESS RELEASE 1998 January 14
24. Elam aims for $1 billion revenues by 2001. SCRIP 1998 2303 12
25. Preliminary studies using parallel synthesis to prepare compounds for an in vivo assay. Freeman J, Ho K, Rivera T, Mayer E, Rosado C, Mahoney R, Leone-Bay A ACS 1998 215 Dallas MEDI 085
26. The prediction of gastrointestinal heparin delivery by acylated non-α-amino acids using immobilized artificial membrane chomatography as an in vitro screen. Harris E, Kalbag S, Leone-Bay A, Paton DR ACS 1998 215 Dallas MEDI 086
27. Acacia Research subsidiary completes private financing. Acacia BioSciences Inc PRESS RELEASE 1998 March 19
28. Emisphere raises $13.5M, plans heparin phase II. BIOWORLD WEEK 1998 6 19 3
29. Emisphere announces initiation of phase II clinical trial for oral heparin product. Emisphere Technologies Inc PRESS RELEASE 1998 May 27
30. Emisphere, Elan add $10M to oral heparin venture. BIOWORLD WEEK 1998 6 32 4
31. Circulation publishes Emisphere's oral heparin phase I clinical data and analysis. Emisphere Technologies Inc PRESS RELEASE 1998 October 20
32. Emisphere reports 1998 fourth quarter and year end financial results. Emisphere Technologies Inc PRESS RELEASE 1998 October 27
33. DRUG DEV PIPELINE 1998 3 7 1-4
34. DRUG DEV PIPELINE 1998 3 9 1
35. Enantioselective acetylide additions: Practical syntheses of non-nucleoside reverse transcriptase inhibitors. Tillyer RD, Grabowski EJJ CURR OPIN DRUG DISCOVERY DEV 1998 1 3 349-357
36. Synthesis and evaluation of compounds that facilitate the gastrointestinal absorption of heparin. Leone-Bay A, Paton DR, Freeman J, Lercara C, O'Toole D, Gschneider D, Wang E, Harris E, Rosado C, Rivera T, DeVincent A et al J MED CHEM 1998 41 7 1163-1171
37. Emisphere and Elan announce positive phase II clinical trial results for oral heparin product. Emisphere Technologies Inc PRESS RELEASE 1999 January 11
38. Heparin absorption across the intestine: effects of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate in rat in situ intestinal instillations and in Caco-2 monolayers. Brayden D, Creed E, O'Connell A, Leipoid H, Agarwal R, Leone-Bay A PHARM RES 1997 14 1772-1779
39. Acylated non-α-amino acids as novel agents for the oral delivery of heparin sodium, USP. Leone-Bay A, Paton DR, Variano B, Leipoid H, Rivera T, Miura Fraboni J, Baughman RA, Santiago N J CONTROL RELEASE 1998 50 1-3 41-49
40. Emisphere announces update on oral heparin development program. Emisphere Technologies Inc PRESS RELEASE 1999 February 25
41. DRUG DEV PIPELINE 1999 4 2
42. Emisphere reports 1999 second quarter and six month financial results. Emisphere Technologies Inc PRESS RELEASE 1999 March 17
43. Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate: Pharmacological considerations. Rivera TM, Leone-Bay A, Paton DR, Liepold HR, Baughman RA PHARM RES 1997 14 1830-1834
44. Emisphere Technologies Inc announces restructuring of relationship with Elan Corp for development and marketing of oral heparin. Emisphere Technologies Inc PRESS RELEASE 1999 July 06
45. Increased throughput in an in vivo assay by use of parallel synthesis. O'Toole DC, Freeman JJ, Rosado C, Ang K, Mayer E, Leone-Bay A ACS 1999 218 New Orleans MEDI 252
46. Emisphere Technologies Inc announces the presentation of its phase II oral heparin results - to be presented at the XVIIth Congress of the International Society of Thrombosis and Haemostasis - August 19, 1999. Emisphere Technologies Inc PRESS RELEASE 1999 August 17
47. Results of Emisphere Technologies phase II patient trial presented today at the XVIIth Congress of the International Society of Thrombosis and Haemostasis - showed oral heparin to be comparable in safety and activity to subcutaneous heparin. Emisphere Technologies Inc PRESS RELEASE 1999 August 19
48. Emisphere Technologies Inc announces phase II clinical and nonclinical data support moving forward into phase III development. Emisphere Technologies Inc PRESS RELEASE 1999 August 24
49. Emisphere Technologies Inc announces start of clinical trials with Novartis compound. Emisphere Technologies Inc PRESS RELEASE 1999 September 08
50. Summary of the American Chemical Society 218th National Meeting, New Orleans, LA, USA. Hutton I IDDB MEETING REPORT 1999 August 22-26
51. Emisphere Technologies finalizes phase III protocol and prepares to initiate phase III clinical development program. Emisphere Technologies Inc PRESS RELEASE 1999 December 15
52. Emisphere Technologies Inc. HAMBRECHT & QUIST 2000 January 10-13 114
53. Chase H&Q 18th Annual Healthcare Conference, San Francisco, CA, USA. Hookes J IDDB MEETING REPORT 2000 January 10-13
54. Oral delivery of low molecular weight heparin in two species. Leone-Bay A, Paton D, Leipold H, Rivera T, Rosado C, Baughman R PROC CONTROL RELEASE SOC 1998 - 25 85-86
55. Increased throughput in an in vivo assay by use of a parallel synthesis. O'Toole DC, Freeman Jr JJ, Rosado C, Ang K, Mayer E, Leone-Bay A PROC CONTR RELEASE SOC 1999 218 1-2 MEDI 252
56. Oral delivery of anticoagulant doses of heparin. A randomised, double-blind, controlled study in humans. Baughman RA, Kapoor SC, Agarwal RK, Kisicki J, Catella Lawson F, Fitzgerald GA CIRCULATION 1998 16 1610-1615
57. The evolution of an oral heparin dosing solution. Leone-Bay A, Leipold H, Agarwal R, Rivera T, Baughman RA DRUGS FUTURE 1997 22 8 885-891
58. Oral and intracolonic delivery of low molecular weight heparin in two species. Rosado C, Rivera T, Baughman RA, Leipold H, Devincent A, Mayer E, Lercara C, Leone-Bay A PHARM RES 1997 14 11 S658
59. Effect of manufacturing process modification on the physico-chemical characteristics and in vivo evaluation of sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC). Chaudhary K, Baly J, Rofail O, Lercara C, Rosado C, Mayer B, Baughman RA, Agarwal RK PHARM RES 1997 14 11 S648-S649
60. The oral absorption of heparin sodium, USP facilitated by a series of novel delivery agents. Leone-Bay A, Paton D, Ho K-K, Freeman J, Lecara C, O'Toole D, Rivera T, Rosado C, Harris E, Baughman R PHARM RES 1997 14 11 S222-S223
61. Heparin absorption across the intestine: effects of sodium N-(8-(2-hydroxybenzoyl)amino)caprylate in Caco-2 monolayers and in rat in situ installations. Brayden DJ, Creed EM, O'Connell A, Leipold H, Agarwal R, Leone-Bay A PHARM RES 1997 14 11 S222
62. Delivery of heparin on intraduodenal administration of o/w emulsions to rats. Meehan E, O'Malley D, Wilson C, Barry J, Scully P J CONTROL RELEASE 1997 46 1-2 192
63. A microinfusor device for the delivery of therapeutic levels of peptides and macromolecules. Meehan E, Gross Y, Davidson D, Martin M, Tsals I J CONTROL RELEASE 1997 46 1-2 107-116
64. Enhancement of TRH and heparin absorption across Caco-2 monolayers by a natural ethoxylated non-ionic medium-chain glyceride oil. Dee JM, Purcell C, Brayden DJ PHARM RES 1997 14 11 S21
65. Pharmacological profile of oral heparin using derivatized non-α-amino acids. Rivera T, Baughman RA, Leipold H, Rosado C, Kutzy T, Mayer E, Leone-Bay A PHARM RES 1996 13 9 S326
66. Acylated non-α-amino acids as novel agents for the oral delivery of therapeutic levels of USP heparin. Leone-Bay A, Variano B, O'Toole D, Lercara C, Ho K-K, Rivera T, Baughman R, Santiago N PHARM RES 1996 13 9 S152
67. Evaluating the PODDS-TM technology in primates. Rivera T, Anderson M, Leone-Bay A, Demorin F, Rosado C, Frommer E, Marchi D, Press J, Santiago N PHARM RES 1995 12 9 S293
68. Screening candidate microsphere formulations by incubating in simulative digestive fluids. Baughman RA, Haas S, Milstein S, Santiago N J CONTROL RELEASE 1994 38 1-3 340-341
69. Oral delivery of heparin microspheres made with modified amino acids. Santiago N, Rivera T, Demorin F, Leone-Bay A PHARM RES 1994 11 10 S298
70. Evaluation in rats of vehicles for the oral delivery of low molecular weight heparin. Santiago N, Mahoney R, Leone-Bay A, Demorin F, Milstein S, Baughman RA PHARM RES 1994 11 10 S298
71. Oral delivery of heparin using acylated amino acids. Leone-Bay A, Achan D, Demorin F, Falzarano L, Lecara C, Mahoney R, O'Toole D, Rivera T, Santiago N, Vuocolo E, Wang N PHARM RES 1994 11 10 S121
72. Stability study of drug-loaded proteinoid microsphere formulations during freeze-drying. Ma X, Santiago N, Chen YS, Chaudhary K, Milstein SJ, Baughman RA J DRUG TARGETING 1994 2 1 9-21
73. Assessment of stability of proteinoid micropsheres. Haas S, Rivera T, Baughman RA, Milstein S, Santiago N PROC CONTR RELEASE SOC 1993 20 340-341
74. Initial studies in the assessment of proteinoid microsphere activity. Santiago N, Rivera T, Wang NF, Maher J, Baughman RA PROC CONTR RELEASE SOC 1993 20 300-301
75. Some factors affecting protein and polysaccharidal drug-loaded proteinoid microsphere formulations. Ma X, Santiago N, Chaudhary K, Milstein SJ, Baughman RA PHARM RES 1993 10 10 S293
76. Emisphere Technologies Inc initiating clinical testing of heparin solid oral dosage form. Emisphere Technologies Inc PRESS RELEASE 2000 March 16
77. Emisphere Technologies Inc announces fiscal 2000 second quarter and six months results. Emisphere Technologies Inc PRESS RELEASE 2000 March 16
78. Emisphere Technologies Inc announces preliminary results from first clinical evaluation of oral heparin capsule dosage form. Emisphere Technologies Inc PRESS RELEASE 2000 April 19
79. Transport of human growth hormone across Caco-2 cells with novel delivery agents: Evidence for P-glycoprotein involvement. Wu S-J, Robinson JR J CONTROL RELEASE 1999 62 1-2 171-177
80. Emisphere Technologies Inc announces fiscal 2000 third quarter and nine month results Emisphere Technologies Inc PRESS RELEASE 2000 June 06
81. Emisphere Technologies Inc publishes efficacy results from two preclinical evaluations of oral heparin and LMWH in DVT treatment. Emisphere Technologies Inc PRESS RELEASE 2000 June 07
82. Treatment of experimentally induced caval thrombosis with oral low molecular weight heparin and delivery agent in a porcine model of deep venous thrombosis. Salartash K, Lepore M, Gonze MD, Leone-Bay A, Baughman R, Sternbergh III WC, Bowen JC, Money SR ANN SURG 2000 231 789-794
83. Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis. Gonze MD, Salartash K, Stembergh, III WC, Baughman RA, Leone-Bay A, Money SR CIRCULATION 2000 101 2658-2661
84. Emisphere Technologies. Chase H&Q ANALYST REPORT 2000 April 20